Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study

[1]  L. Coates,et al.  OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021 , 2021 .

[2]  N. Wei,et al.  Psoriatic Arthritis: What is Happening at the Joint? , 2019, Rheumatology and Therapy.

[3]  L. Gossec,et al.  Quality of life in psoriatic arthritis , 2018, Expert review of clinical immunology.

[4]  C. Edwards,et al.  Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial , 2018, Rheumatology.

[5]  L. Coates,et al.  Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations , 2016, Nature Reviews Rheumatology.

[6]  M. Cutolo,et al.  A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial , 2016, The Journal of Rheumatology.

[7]  A. Gottlieb,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis , 2016, Arthritis & rheumatology.

[8]  A. Ogdie,et al.  Patient-Reported Outcomes in Psoriatic Arthritis. , 2016, Rheumatic diseases clinics of North America.

[9]  C. Edwards,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) , 2016, Annals of the rheumatic diseases.

[10]  C. Ritchlin,et al.  Etiology and Pathogenesis of Psoriatic Arthritis. , 2015, Rheumatic diseases clinics of North America.

[11]  A. Ogdie,et al.  The Epidemiology of Psoriatic Arthritis. , 2015, Rheumatic diseases clinics of North America.

[12]  P. Mease.  Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis , 2014, Rheumatology and Therapy.

[13]  F. de Keyser,et al.  Assessment of Activity Limitations with the Health Assessment Questionnaire Predicts the Need for Support Measures in Patients with Rheumatoid Arthritis: A Multicenter Observational Study , 2014, PloS one.

[14]  R. Poole,et al.  Apremilast: First Global Approval , 2014, Drugs.

[15]  M. D. de Wit,et al.  A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative , 2014, Annals of the rheumatic diseases.

[16]  A. Gottlieb,et al.  Apremilast for the treatment of psoriatic arthritis , 2014, Expert review of clinical pharmacology.

[17]  L. Misery,et al.  Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  Y. Leung,et al.  Measuring Disease Activity in Psoriatic Arthritis , 2012, International journal of rheumatology.

[19]  A. Menter,et al.  Psoriatic Arthritis: An Update , 2012, Arthritis.

[20]  G. Schett,et al.  Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases , 2010, Therapeutic advances in musculoskeletal disease.

[21]  C. Ritchlin.  Pathogenesis of psoriatic arthritis , 2005, Current opinion in rheumatology.

[22]  D. Gladman,et al.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome , 2005, Annals of the rheumatic diseases.

[23]  D. Gladman,et al.  Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. , 1998, Arthritis and rheumatism.

[24]  P. Mease.  Psoriatic arthritis - update on pathophysiology, assessment, and management. , 2010, Bulletin of the NYU hospital for joint diseases.

[25]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF PSORIATIC ARTHRITIS , 2005 .